As technological advances unlock a more nuanced understanding of disease – and exciting opportunities for personalised medicine – some cancers are now being redefined as rare diseases.
The grey matter in the brain may hold vital clues for early, accurate detection in Alzheimer’s, and potentially also help pharma to find new drug treatments.
As specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers are scrutinising the economic value of new treatments more
COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities, and it will likely have a lasting impact on market access.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
